The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
 
Ryan J. Sullivan
Honoraria - Roche/Genentech
Consulting or Advisory Role - ACI Clinical; Amgen; Array BioPharma; Biodesix; BiolineRx; Merck; Novartis; Takeda; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Other Relationship - Boehringer Ingelheim
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Anthony W. Tolcher
Employment - New Experimental; START
Leadership - Symphony Evolution
Consulting or Advisory Role - AbbVie (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Elekta (Inst); EMD Serono (Inst); Formation Biologics (Inst); Genmab (Inst); Idea Pharma (Inst); Ignyta (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); Alexion Pharmaceuticals (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst)
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - G1 Therapeutics; Lilly; Merck Serono; Pfizer; Roche; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); CanBas (Inst); Cellceutix (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Lilly (Inst); Merck Serono; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology; Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; PACT Pharma; Tango Therapeutics
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis
 
Les H. Brail
Employment - Infinity Pharmaceuticals; Neon Therapeutics
 
Jennifer Roberts
Employment - Infinity Pharmaceuticals; Tokai Pharmaceuticals
 
Lucy Lee
Employment - Immunomedics; Infinity Pharmaceuticals
 
Brenda O'Connell
Employment - Infinity Pharmaceuticals
 
Jeffrey Lorne Kutok
Employment - Infinity Pharmaceuticals
 
Suresh Mahabhashyam
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
Travel, Accommodations, Expenses - Infinity Pharmaceuticals
 
Claudio Dansky Ullmann
Employment - Infinity Pharmaceuticals
 
Michael A. Postow
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Novartis (Inst); Rgenix; Rgenix
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Adaptive Biotechnologies; Imvaq Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics
Honoraria - Regeneron
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Ascentage Pharma; Beigene; Bristol-Myers Squibb; Chugai Pharma; FSC Pediatrics; Genentech; Lilly; MedImmune; Merck; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; Sellas Life Sciences; Tizona Therapeutics, Inc.
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Chugai Pharma; Janssen; Ono Pharmaceutical; Roche